Skip to main content

HomeResearchAc-SDKP

CategoryRecovery
SafetyLow Risk
StatusResearch Only

Ac-SDKP

N-acetyl-seryl-aspartyl-lysyl-proline · AcSDKP

CategoryRecovery
Half-life
Routesubcutaneous, intravenous
RiskLow Risk
ProvidersNone listed

About Ac-SDKP

Inhibits hematopoietic stem cell entry into S-phase. Blocks TGF-β1-mediated fibroblast activation, reducing collagen deposition. Promotes angiogenesis via VEGF upregulation. Regulated in vivo by ACE enzyme.

A naturally occurring tetrapeptide derived from thymosin beta-4 cleavage by prolyl oligopeptidase. Potent anti-fibrotic properties studied in cardiac, pulmonary, and renal fibrosis. Also promotes angiogenesis and wound healing.

Research Areas

anti-fibroticcardiac repairwound healingkidney protection

Regulatory & Evidence

Risk Profile

Low Risk

Generally considered lower risk in research contexts. Risk profile varies by individual — review contraindications before use.

Regulatory Status

Availability Status
Research Only

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Safety Notes

Low Risk

Generally considered lower risk in research contexts. Individual response varies — review all considerations before use.

Reported contraindications & considerations

Pregnant Or Nursing

Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.

Where to Find Ac-SDKP

Coverage expanding

No verified providers currently list Ac-SDKP. Get notified when one does, or explore providers carrying similar peptides in the Recovery category.

Frequently Asked Questions — Ac-SDKP

A naturally occurring tetrapeptide derived from thymosin beta-4 cleavage by prolyl oligopeptidase. Potent anti-fibrotic properties studied in cardiac, pulmonary, and renal fibrosis.

anti-fibrotic, cardiac repair, wound healing, kidney protection.

Newsletter

The Peptide Research Digest

New providers, emerging stacks, and research developments — weekly.

No spam. Unsubscribe anytime. Privacy policy.